改进分子诊断方法来确定个体患病风险；(2)进行癌症和其他疾病的可治愈早期诊断；(3)提供预后信息并调控治疗反应。Leland H. Hartwell博士近年来在美国和世界范围内开展了许多项目以支持分子诊断的团队研究和促进新技术的开发。他现在担任个性化医疗合作组织（PPM）执行委员会主席，该委员会致力于与国际医疗卫生系统展开合作，以开发和验证具有低成本高效的疾病管理生物标记物和相应分子诊断方法。
Dr. Leland H.Hartwell is President and Director of Seattle's Fred Hutchinson Cancer Research Center and recipient of the 2001 Nobel Prize in Medicine or Physiology.
Dr. Hartwell received his bachelor's degree from the California Institute of Technology in 1961. In 1964, he received his PhD in biology from the Massachusetts Institute of Technology. From 1965 to 1968, he worked at the University of California as a professor. He moved to the University of Washington in 1968. In 1996, Hartwell joined the faculty of Fred Hutchinson Cancer Research Center and in 1997 became its president and director.
Dr. Hartwell's primary research contributions were in identifying genes that control cell division in yeast and the processes that assure its accuracy. Subsequently many of these same genes have been found to control cell division in humans and often to be the site of alteration in cancer cells.
Recently his interests have turned to how our increasing understanding of biology can be used to improve healthcare. He believes that the most efficient path is to improve molecular diagnostics to identify individuals at high risk for disease, detect cancer and other diseases at an early stage when they can be cured, provide prognostic information and monitor therapeutic response. He has directed his efforts recently to national and international projects to support team science in molecular diagnostics and stimulate new technology development. He currently chairs the executive committee of the Partnership for Personalized Medicine, which is committed to engaging healthcare systems internationally in the discovery and validation of biomarkers for cost-effective disease management. Dr. Hartwell will visit China during November 16-20, 2009. The primary goal of this visit is to develop a collaborative project for Improving Healthcare Outcomes and Reducing Costs based on the Discovery and Implementation of new Disease Biomarkers.